Spyre Therapeutics price target raised to $98 from $70 at BTIG

BTIG analyst Julian Harrison raised the firm’s price target on Spyre Therapeutics (SYRE) to $98 from $70 and keeps a Buy rating on the shares. Phase 2 Part A data of SPY001 supports best-in-class efficacy in both in naive and advanced treatment-experienced ulcerative colitis, says the analyst, who is raising the firm’s view of the odds of success for SPY001 combos in UC to 80% following the results.